Today, Mylan offers more than 1,400 products internationally, making it “one of the largest generics and specialty pharmaceutical companies in the world” (“Company,” 2016). Mylan’s website emphasizes on increasing global manufacturing, innovation, and generic utilization (“Company,” 2016). Over the years, they have expanded globally through the acquisition of a number of businesses, including the acquisition of Merck KGaA in 2007, in which Mylan attained the rights to EpiPen (“Company,” 2016). More recently, in August 2016, Mylan acquired Meda, which cost about $7.2 billion (Drozdiak, 2016). In addition to expansion, they are constantly working on the improvement of existing products, as shown with multiple generations of EpiPen, as well as the development of new and generic products.…